USL255
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Objective: Compare efficacy and safety of once-daily USL255 (Qudexy ® XR [topiramate] extended-release capsules) and other second…
USL255 is a once-daily, extended-release formulation of the well-established antiepileptic drug topiramate that was recently…
OBJECTIVE: Compare the PK and TEAE profiles of USL255 with immediate-release topiramate (TPM-IR [Topamax ® ]) after multiple-dose…
OBJECTIVE: Evaluate early efficacy and timing of treatment-emergent adverse events (TEAEs) with USL255, a once-daily extended…
OBJECTIVE: Gain an understanding of pharmacokinetic effects associated with delayed administration of USL255.
BACKGROUND: USL255…
OBJECTIVE: Evaluate efficacy, safety, and impact on quality of life (QoL) of adjunctive treatment with USL255, once-daily…
OBJECTIVE: Evaluate the adverse event profile of USL255, once-daily extended-release (XR) topiramate, in adults with refractory…
OBJECTIVE: Assess the efficacy of USL255, once-daily extended-release topiramate, in patients subdivided by baseline seizure type…
OBJECTIVE: Evaluate bioequivalence between USL255 beads sprinkled onto soft food compared with the intact USL255 capsule…
Objective: Evaluate dose proportionality, linearity, and tolerability of USL255 at 25, 50, 100, 200, and 400 mg. Background…